Webinars & Presentations UCSF: High efficiency cell engineering Seminar with Stanford Researchers at Dr. Steve Feldman’s Lab

Join us for a Seminar on High Efficiency Cell Engineering  with Stanford Researchers at Stanford University

Join us live from Stanford University for a Seminar on High Efficiency Cell Engineering

Thursday, June 13, 2024
12:00 PM - 1:30 PM (PT)

If you can't attend in-person,
register to attend for the virtual event

In-person
Stanford University
BMI Building (BioMedical Innovation Building)
Room 1021
240 Pasteur Drive
Palo Alto, CA

About the event

Are you involved in cell engineering research and eager to bridge the gap from the lab to real-world clinical applications?

We invite you to an informative seminar on Scalable Cell Engineering from 12:00 to 1:30 (PT) pm for a Cell Engineering Seminar hosted by the Steve Feldman Lab at Stanford.

Hear from our special guest speaker, Vimal Keerthi, who will present his work utilizing the MaxCyte platform on homology-independent targeted insert for CAR-T cell generation at clinical scale. Our MaxCyte presenters will also demonstrate how customers use the MaxCyte scalable transfection platform to edit primary cells, stem cells, and other hard-to-transfect cell lines while maintaining high efficiency and viability regardless of application.

Register to learn more about how academic & and industry labs utilize MaxCyte and FCDI's enabling technologies to efficiently engineer primary cells, stem cells, and cell lines all while maintaining high cell viabilities & recovery.

RSVP to the in-person seminar by filling out the form.

Lunch on us: we value your time, and to keep the focus on learning, we're providing a complimentary lunch for all attendees. If you have any questions related to this event, please contact Genevieve Soares.

Hosts

Picture of Vimal Keerthi

Vimal Keerthi

Process Development Scientist
Dr. Steven Feldman’s Lab Stanford Laboratory of Cell and Gene Medicine Stanford Center for Cancer

Vimal is a Process Development Scientist in Dr. Steven Feldman’s group at the Stanford Center for Cancer Cell Therapy focusing on developing CRISPR knock-in platforms for non-viral CAR-T manufacturing. Prior to working on non-viral platforms, Vimal worked on the process development of Allogeneic Hematopoietic Stem Cell Transplants and donor derived T-allo10 Tr1 cell therapies at Stanford’s cGMP Laboratory of Cell & Gene Medicine.

 

Darlin Nungo Pinzon

Darlin Nungo Pinzon

Northwest Account Manager
Discovery Research
FUJIFILM Irvine Scientific

Darlin has over eight years of experience in the life sciences industry and has dedicated the past two years to working exclusively with fully differentiated human-derived induced pluripotent stem cells (iPSCs) at Fujifilm Cellular Dynamics. Darlin's expertise lies in providing these iPSCs for groundbreaking applications in drug discovery, safety and toxicology assessment, and disease modeling. Darlin's work represents a commitment to advancing our understanding of human biology and developing innovative approaches to address complex medical challenges.

 

Lucy Yang

Lucy Yang,PhD

Field Application Scientist
MaxCyte, Inc.

After completing her Bachelor’s in Bioengineering at MIT, Lucy finished her PhD in Bioengineering at the University of Washington last year. Her research expertise includes drug delivery, DNA aptamers and chemistry, CRISPR/Cas9 genome editing, and polymer chemistry. Based in Seattle, Lucy currently supports our collaborators throughout the Pacific Northwest and the Bay area.

 

Genevieve Soares

Genevieve Soares

Senior Business Development Manager
MaxCyte, Inc.

Genevieve Soares joined the MaxCyte family in 2022 after 14 years serving scientists in western US and Canada in various positions at PeproTech.  As Senior Sales Manager in the Bay Area, she supports industry accounts in cell and gene therapy, bioprocessing and drug discovery.   She is passionate about scientific innovation and supporting the scientific community in their continuous search to cure diseases.

RSVP

Registration to this webinar is now closed.